|
|
|
|
Cell Cycle Kinases as Therapeutic Targets for Cancer
Newswise - A comprehensive overview that explores the prospects and progress of synthetic inhibitors to target cell cycle kinases in cancer forecasts that 'novel compounds with increased potency, improved kinase specificity and...
|
|
|
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preli
Print Save in My Library Free Full Text Fluge O et al.- B-lymphocytes are involved in CFS pathogenesis for a subset of patients. Benefit for all CFS symptoms, the delayed symptom relief following B-cell depletion, the...
|
|
|
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrom
_ Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrom.
|
|
|
Hepatitis B Virus - Studies from K. Szymanska et al have provided new data on hepatitis B virus
Learn more about a six-week, no-risk free trial of Hepatitis Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Hepatitis B Virus Studies from K. Szymanska et al have...
|
|
|
Hepatitis B Virus - Scientists at University of Tokyo target hepatitis B virus
Learn more about a six-week, no-risk free trial of Hepatitis Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Hepatitis B Virus According to recent research published in...
|
|
|
Academy Sends Congress a Solution to Fix Broken Physician Payment System
Newswise The American Academy of Neurology Professional Association has sent a letter to Congress offering a solution to fix the way physicians are reimbursed under Medicare for treating patients with severe or disabling chronic...
|
|
|
JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta...
|
|
|
ASIA impairment scale conversion in traumatic SCI: is it related with the ability to walk? A descriptive compa
J J van Middendorp1, A J F Hosman1, M H Pouw1, EM-SCI Study Group and H Van de Meent2 1Spine Unit, Department of Orthopaedics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands 2Department of Rehabilitation Medicine,...
|
|
|
2. Personalized Anti-Cancer Vaccine, BiovaxID[R], Targeting B-cell Lymphomas
Biovest and idis Partner to Facilitate Patient Access to Lymphoma Vaccine Phase III Study Results to Be Presented at 'Best of ASCO' in Paris TAMPA, Fla.-- Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of...
AllBusiness Champions of Small Business:
Jul 1 2009 4:59PM
Matching: leukemia b cell chronic
|
Find similar documents
|
|
|
|
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomela
Agomelatine is a novel antidepressant acting as a melatonergic receptor agonist and serotonergic (5-HT2C) receptor antagonist.In adult rats, chronic agomelatine treatment enhanced cell proliferation and neurogenesis in the...
|
|
|
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomela
Agomelatine is a novel antidepressant acting as a melatonergic receptor agonist and serotonergic (5-HT2C) receptor antagonist.In adult rats, chronic agomelatine treatment enhanced cell proliferation and neurogenesis in the...
|
|
|
BiovaxID Now Available In Europe
BiovaxID, a therapeutic anti-cancer vaccine produced by Biovest, a subsidiary of Accentia Biopharmaceuticals, is now available in Europe.BiovaxID is a personalised vaccine, which uses the patient's own immune system to treat follicular...
|
|
|
Nuclear-plant workers face elevated cancer risk: report
The 30-page Exposure to Radiation and Health Outcomes, commissioned by the Saskatchewan Union of Nurses and the Canadian Centre for Policy Alternatives, found that chronic exposure to low doses of radiation causes the higher risk.A...
|
|
|
Childhood cancer survivors sicker as adults
People who survived childhood brain cancer were 13 times more likely to die within 30 years than others their age, a study found.The most common cause of death was recurrence of their brain cancer, according to research in the July 1...
|
|
|
Hyperion Therapeutics Raises $60 Million Series C
SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and...
|
|
|
Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-Cell Lymphomas Available In Europe On A Named-Patie
Biovest International, Inc.(Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID, Biovest's personalized therapeutic anti-cancer vaccine, is available on a...
|
|
|
Biovest' BiovaxID Now Available In Europe
BiovaxID, to stimulate the patient' own immune system to recognize and destroy cancerous B-cells Biovest, a subsidiary of Accentia Biopharmaceuticals, has announced that BiovaxID, a personalized therapeutic anti-cancer vaccine,...
|
|
|
Minicells defeat drug resistant cancer
Researchers led by Sydney-based biotechnology company, EnGeneIC, have reported in Nature Biotechnology that bacterially-derived minicells can be used to target previously resistant cancerous tumours, presenting the possibility of treating...
|
|
|
Peptic ulcer bacterium alters the body's defence system
Helicobacter pylori survives in the body by manipulating important immune system cells.This is shown in a thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden. The discovery may lead to new treatments against the...
|
|
|
Innate Pharma Reports Positive Phase IIa Clinical Results For Iph 1101 In Type C Viral Hepatitis
Innate Pharma (Euronext Paris: FR0010331421 IPH) reports positive results for its first Phase IIa clinical trial with IPH 1101 (a small-molecule ?d T cell agonist) in patients with type C viral hepatitis (HCV).In this open-label...
|
|
|
Seeking drug plan Solutions
Finding ways to manage chronic disease in the workplace is a growing issue for sponsors of employee drug plans concerned about ongoing cost increases.Thats the topic addressed by speakers at this years Solutions in Drug Plan...
|
|
|
Personalized Anti-Cancer Vaccine, BiovaxID, Targeting B-cell Lymphomas Available in Europe on a Named-Patien
News source: Business Wire Biovest International, Inc.(Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID, Biovests personalized therapeutic anti-cancer...
|
|
|
Personalized Anti-Cancer Vaccine, BiovaxID, Targeting B-cell Lymphomas Available in Greece and Cyprus on a N
Biovest International, Inc.(Other OTC: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ) today announced that BiovaxID, Biovests personalized therapeutic anti-cancer vaccine, is available on a...
|
|
|
Personalized Anti-Cancer Vaccine, BiovaxID, Targeting B-cell Lymphomas Available in Europe on a Named-Patien
Biovest International, Inc.(Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID, Biovests personalized therapeutic anti-cancer vaccine, is available on a...
|
|
|
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
AbstractThe mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy; however, CLL is still an incurable disease with resistance to therapy developing in the majority of patients.In recent years, our...
Nature Clinical Practice Oncology:
Jun 29 2009 7:42AM
Matching: leukemia b cell chronic
|
Find similar documents
|
|
